On Body Injector: The Goldrush Continues

The on body injector market is currently characterized by the presence of a myriad of advanced and innovative drug delivery technologies, equipped with a variety of user-friendly features. Notable examples of such products include prefilled syringes, reusable and disposable pen injectors, autoinjectors and large volume wearable injectors. On body injector is capable of drug delivery primarily via the subcutaneous route and have become a preferred choice for administration of drugs in the home-care setting. Variants of these wearable devices have been designed to administer highly viscous drugs (such as most biologics) in large volumes (more than 1 ml), offering numerous benefits, such as ease-of-use, reduced chances of dosing-related errors, integrated safety mechanisms, and an almost negligible risk of needlestick injuries. It is worth highlighting that such devices have captured the interest of several stakeholders in this industry to deliver various insulin and non-insulin drugs.


Opinions expressed by industry stakeholders acknowledge the significant potential of on body injector in improving and simplifying the drug administration process.


Many companies have undertaken diverse initiatives to develop self-injection devices for convenient, patient-friendly delivery of drugs.


Several marketed on body injectors are currently present in the market; of these, a significant proportion are designed to administer relatively high drug volumes in bolus or continuous doses

Over 65% of wearable injectors are currently under development. Additionally, majority (~40%) of injectors are capable of delivering 2-6 mL of non-insulin drugs.

In fact, companies developing devices for insulin delivery have already established a strong position in this domain

Over 45 wearable injectors are capable of delivering insulin for the treatment of patients suffering from diabetes. Further, close to 65% of the devices are commercially available in market.

The benefits of on body injector for delivery of insulin are evident across social media platforms, such as Twitter.


In order to achieve a competitive edge, device developers continue to invest in incorporating advanced features in proprietary products to further strengthen their product portfolios.


Outsourcing is a popular trend; presently, there are several CMOs across the world capable of producing delivery devices and their components.


Over the years, more than 2,000 patents have been granted / filed related to on body injector devices, demonstrating the heightened pace of research in this domain

The rising interest of stakeholders can be attributed from the rising number of patents that have been filed / granted for wearable injectors

An evaluation of both marketed / pipeline products reveals several drugs / product candidates that are likely to be considered for administration via large volume wearable injectors.


Given the increasing incidence of chronic conditions and the growing pipeline of drugs, the market for wearable injectors is poised to grow at a CAGR of ~40% till 2030.


Primarily centered in the developed regions, the long term opportunity is likely to be distributed across different devices based on their type and usability.


To learn more, please click Wearable Injectors Market. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com. You can also download the SAMPLE REPORT on on body injector by Roots Analysis.


Our Social Media Platform

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com